Senior Scientist – Cell Production & Tissue Engineering
United Therapeutics Corporation
Summary
Working in a fast-paced and collaborative environment, the Senior Scientist will help establish manufacturing strategies and process controls that enable the reliable production of personalized grafts while meeting quality, regulatory, and operational requirements. The successful candidate will apply deep scientific expertise in stem cell biology, tissue engineering, and cell manufacturing to solve complex technical challenges, improve process performance, and support the progression of therapies from development through clinical and commercial manufacturing.
Job description
- Lead the development and implementation of robust process methods for the production of primary and/or iPS-derived renal cells
- Lead the development and implementation of methods to mature iPS-derived renal cell phenotypes functionally and develop and implement physiologic assays to test this function in vitro
- Lead and contribute to cell production efforts, including both internal and external manufacturing, to ensure the availability of high-quality cells for R&D cellularization initiatives supporting advanced organ therapeutics
- Contribute to academic and industry collaborations and facilitate technology transfer activities, ensuring seamless integration of external innovations and methodologies into internal laboratory processes
- Develop, implement, and oversee analytical methods for characterizing the quality and suitability of iPS-derived cells used in the generation of 3D printed organs
- Independently and collaboratively design, execute, and oversee complex laboratory experiments and projects that advance program objectives
- Exercise independent judgment in evaluating, selecting, and substantially adapting or modifying standard techniques, procedures, and criteria
- Participate in the selection, acquisition, and implementation of laboratory equipment, ensuring alignment with research needs and operational efficiency
- Develop, author, and review laboratory methods and protocols, ensuring scientific rigor, reproducibility, and compliance with regulatory standards
- Act as a scientific lead in evaluating new technologies for future process development
- Collaborate with manufacturing team to ensure process and methods for production of iPS-derived cells are GMP ready
- Author and contribute to scientific publications and presentations at conferences
- Lead or support patent and publication efforts, including the development of protocols, abstracts, posters, manuscripts, and study reports
- Prepare and contribute to intellectual property (IP) and regulatory filings, ensuring that documentation meets internal and external requirements for innovation protection and compliance
- May direct and manage team to include responsibilities for goal setting, performance reviews/management, coaching, mentoring and career development
- Mentor and guide Associate Scientists and junior team members in research direction and experimental design
Requirements
- Bachelor's Degree in biomedical engineering, cell biology, molecular biology, or other related discipline or Master's Degree in biomedical engineering, cell biology, molecular biology, or other related discipline or Doctor of Philosophy (PhD) in biomedical engineering, cell biology, molecular biology, or other related discipline
- 10+ years of relevant experience including experience in stem cell differentiation, reprogramming, bioreactor cell production scale up, regenerative medicine with a Bachelor's Degree
- 8+ years of relevant experience including experience in stem cell differentiation, reprogramming, bioreactor cell production scale up, regenerative medicine with a Master's Degree
- 5+ years of relevant experience including experience in stem cell differentiation, reprogramming, bioreactor cell production scale up, regenerative medicine, tissue engineering with a PhD
- Technical expertise in iPS-reprogramming and/or expansion and differentiation methods
- Ability to formulate hypotheses and design and perform sophisticated, technically challenging, and often novel experiments
- Ability to identify the broad implications to findings, which transcend the immediate experiment
- Ability to analyze and distill complicated, multi-dimensional data and synthesize results into a cohesive body of conclusions or recommendations for increasingly complex and diverse studies
- Ability to identify, interpret, and disseminate relevant knowledge from publications in a broader scientific area
- Experience with laboratory instrumentation and data software; Facility with appropriate word processing, spreadsheet, presentation and related standard software
- Ability to mentor and motivate team members
- Advanced written and oral communication skills
- Experience in iPSC differentiation to endothelial and renal epithelial cells
- Expertise in automated cell processing equipment such CliniMACS Plus, FACS, LOVO, Cue, Sepax, Sefia, Rotea and others
- Knowledge in transfer of R&D cell expansion methods to GMP
- Technical expertise in cell bioreactor culture including Ambr systems and vertical wheel bioreactors with scales up to 10L+
Benefits
- Medical, Dental & Vision
- Prescription Coverage
- Employee Wellness Resources
- 401(k) & ESPP
- Paid Time Off
- Paid Parental Leave
- Disability Benefits
Company overview
United Therapeutics Corporation is an American biotechnology company founded in 1996 with a deeply personal mission: to find a cure for pulmonary arterial hypertension (PAH) after the founder's daughter was diagnosed with this rare disease. Headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, the company has evolved into a pioneering force in biotechnology, focusing on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. United Therapeutics specializes in treatments for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, neuroblastoma, and end-stage lung disease through its flagship products including Tyvaso, Remodulin, Orenitram, Adcirca, and Unituxin. The company is particularly notable for being the first publicly-traded biotech or pharmaceutical company to convert to a public benefit corporation (PBC), with a dual purpose of developing innovative pharmaceutical therapies and creating technologies that increase transplantable organ availability. Their groundbreaking work includes xenotransplantation research, organ manufacturing technologies, and regenerative medicine programs aimed at addressing critical shortages in transplantable organs. With approximately 1,001-5,000 employees and a strong commitment to corporate social responsibility, United Therapeutics has established itself as a leader in both patient-focused innovation and workplace excellence.